<DOC>
	<DOCNO>NCT00456846</DOCNO>
	<brief_summary>The purpose study determine toxicity anti-tumor activity nab-paclitaxel 100mg/m^2 administered weekly 4-week cycle first line therapy patient metastatic breast cancer receive taxanes part adjuvant therapy patient receive taxanes part adjuvant therapy .</brief_summary>
	<brief_title>First Line Therapy Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>This open-label , phase II study determine toxicity antitumor activity ABI-007 100 mg/m2 administer weekly 3 week follow rest week ( 4-week cycle ) first line therapy patient metastatic breast cancer follow 2 cohort : Patients receive taxane part adjuvant therapy , patient receive taxane part adjuvant therapy . Patients assess antitumor response every 8 week . The last subject receive study treatment 11DEC2012 . The study terminate 31 May 2013 via notification letter investigator 14 May 2013 .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Females pathologically confirm adenocarcinoma breast . No prior chemotherapy metastatic breast cancer At least 12 month completion adjuvant chemotherapy diagnosis metastatic disease Stage IV disease Measurable disease ( must equal great 2.0 cm use conventional Computed Tomography ( CT ) equal great 1.0 cm use spiral CT except pulmonary lesion well document conventional CT scan must equal great 1.0 cm ) At least 4 week since radiotherapy , full recovery . The measurable disease must completely outside radiation portal must radiologic clinical exam proof progressive disease within radiation portal At least 4 week since major surgery , full recovery Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Age equal great 18 Patients follow blood count Baseline : Absolute Neutrophil Count ( ANC ) equal great 1.5 x 10^9 cells/L Platelets equal great 100 x 10^9 cells/L Hemoglobin ( Hgb ) equal great 90 grams/L Patients follow blood chemistry level Baseline : Aspartate aminotransferase ( AST ) Serum glutamicoxaloacetic transaminase ( SGOT ) , alanine aminotransferase ( ALT ) serum glutamic : pyruvic transaminase ( SGPT ) less equal 2.5x upper limit normal range ( ULN ) ; total bilirubin normal ( unless bilirubin elevation due Gilbert 's ( Disease ) ; alkaline phosphatase less equal 2.5x ULN ( unless bone metastasis present absence liver metastasis ) ; Creatinine le equal 1.5mg/dL Current sensory neuropathy Grade 0 1 Breast Cancer Index ( BCI ) Common Toxicity Criteria Adverse Events ( CTCAE ) If female childbearing potential , pregnancy test negative ( within 72 hour first dose study drug ) . If fertile , patient agrees use effective method contraception avoid pregnancy duration study Patient able supply unstained slide 1 tumor block primary breast tumor biopsy current site metastasis Secreted protein acidic rich cysteine ( SPARC ) analysis Informed consent obtain Concurrent immunotherapy hormonal therapy ( Herceptin ) breast cancer Parenchymal brain metastasis , unless document clinically radiographically stable least 6 month treatment Serious intercurrent medical psychiatric illness , include serious active infection History class IIIV congestive heart failure History malignancy within last 5 year could affect diagnosis assessment breast cancer , exception basal squamous cell carcinoma skin carcinoma situ cervix Patients receive investigational drug within previous 3 week Patient currently enrol different clinical study investigational procedure perform investigational therapy administer . Also patient may enroll clinical trial participate study . Pregnant nursing woman Patients prior hypersensitivity Taxol Taxotere</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Metastatic Breast Cancer , ABI-007 , Abraxane</keyword>
</DOC>